pulmonary hypertension

ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements

ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.

YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients

YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension

An adaptive clinical study programme for IKT-001 in Pulmonary Arterial Hypertension (PAH) was presented at ATS 2026, detailing a novel approach to trial design.